Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17650413 | 0.86 | ABCB11 (0.33) | ABCB11ALDH1A1NR3C1CYP1A2CYP3A4 | |
| SCHEMBL25230727 | 0.82 | ABCB11 (0.32) | ABCB11ALDH1A1NR3C1CYP1A2CYP3A4 | |
| SCHEMBL17650280 | 0.82 | CYP3A4 (0.32) | ABCB11ALDH1A1NR3C1CYP1A2CYP3A4 | |
| SCHEMBL2768908 | 0.82 | ALDH1A1 (0.46) | ABCB11ALDH1A1NR3C1CYP1A2CYP3A4 | |
| SCHEMBL28554406 | 0.79 | TDP1 (0.44) | ALDH1A1CYP3A4HPGDTDP1GABRA1 | |
| SCHEMBL30940600 | 0.78 | ALDH1A1 (0.36) | ABCB11ALDH1A1NR3C1CYP1A2CYP3A4 | |
| SCHEMBL3229637 | 0.78 | ALDH1A1 (0.36) | ABCB11ALDH1A1NR3C1CYP1A2CYP3A4 | |
| SCHEMBL1966386 | 0.77 | GABRA1 (0.39) | MIFGABRA1GABRB2 | |
| SCHEMBL17650560 | 0.75 | ALDH1A1 (0.37) | ABCB11ALDH1A1NR3C1CYP1A2CYP3A4 | |
| SCHEMBL1093861 | 0.75 | ABCB11 (0.32) | ABCB11ALDH1A1NR3C1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3822274-B1 | SYNTHETIC INTERMEDIATES USEFUL FOR PREPARING SUBSTITUTED AMINOPURINE COMPOUNDS | SIGNAL PHARM LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230158035-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2023-05-25 | — | — | US | disclosed |
| US-11590139-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| EP-3822274-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20210128565-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2021-05-06 | — | — | US | disclosed |
| US-10940152-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2021-03-09 | — | — | US | disclosed |
| EP-3204386-B1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2021-03-03 | — | — | EP | disclosed |
| US-20200237768-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2020-07-30 | — | — | US | disclosed |
| US-10646493-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190336507-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2019-11-07 | — | — | US | disclosed |
| US-10398700-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190091230-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2019-03-28 | — | — | US | disclosed |
| US-10149849-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2018-12-11 | — | — | US | disclosed |
| US-20170296546-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2017-10-19 | — | — | US | disclosed |
| US-9737541-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-08-22 | — | — | US | disclosed |
| EP-3204386-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2017-08-16 | — | — | EP | disclosed |
| US-20170042902-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2017-02-16 | — | — | US | disclosed |
| US-9512124-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2016-12-06 | — | — | US | disclosed |
| WO-2016057370-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160096841-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170042902-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, TYMP | ABCB11 2815/4885ALDH1A1 332/4885NR3C1 1914/4885 |
| US-20190091230-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, TYMP | ABCB11 2815/4885ALDH1A1 332/4885NR3C1 1914/4885 |
| US-20160096841-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, TYMP | ABCB11 2815/4885ALDH1A1 332/4885NR3C1 1914/4885 |
| US-20200237768-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, TYMP | ABCB11 2815/4885ALDH1A1 332/4885NR3C1 1914/4885 |
| US-10149849-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | TPMT, MGMT, TYMP | ABCB11 2815/4885ALDH1A1 332/4885NR3C1 1914/4885 |
| US-10940152-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | TPMT, MGMT, TYMP | ABCB11 2815/4885ALDH1A1 332/4885NR3C1 1914/4885 |
| US-20170296546-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, TYMP | ABCB11 2815/4885ALDH1A1 332/4885NR3C1 1914/4885 |
| US-20230158035-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, TYMP | ABCB11 2815/4885ALDH1A1 332/4885NR3C1 1914/4885 |
| US-20190336507-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, TYMP | ABCB11 2815/4885ALDH1A1 332/4885NR3C1 1914/4885 |
| US-10646493-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | TPMT, MGMT, TYMP | ABCB11 2815/4885ALDH1A1 332/4885NR3C1 1914/4885 |
| US-11590139-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | TPMT, MGMT, TYMP | ABCB11 2815/4885ALDH1A1 332/4885NR3C1 1914/4885 |
| US-20210128565-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, TYMP | ABCB11 2815/4885ALDH1A1 332/4885NR3C1 1914/4885 |
| US-10398700-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | TPMT, MGMT, TYMP | ABCB11 2815/4885ALDH1A1 332/4885NR3C1 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.